By Professor Michael Leonard Friedlander

Journal articles

Mitchell P; Goldstein D; Beale P; Friedlander ML; Zalcberg J; White S; Thomson JA; Clarke S; Michael M, 2006, 'Addition of Gabapentin to a Modified FOLFOX Regimen Does Not Reduce Oxaliplatin-Induced Neurotoxicity', Clinical Colorectal Cancer, 6, pp. 146 - 151

Aghmesheh M; Suo Z; Friedlander ML; Nesland J; Kaern J; Stewart MP; Dorum A; Tucker K; Buckley MF, 2006, 'Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas', Pathology, 38, pp. 145 - 151

Goldstein D; Bennett BK; Friedlander ML; Davenport TA; Hickie IB; Lloyd AR, 2006, 'Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study', BMC Cancer, 6, pp. 240 - 240, http://dx.doi.org/10.1186/1471-2407-6-240

Crockford G; Linger R; Hockley S; Dudakia D; Johnson L; Huddart R; Tucker K; Friedlander ML; Phillips KA; Hogg DW; Jewett M; Lohynska R; Daugaard G; Richard S; Chompret A; Bonaiti-Pellie C; Heidenreich A; Albers P; Olah E; Geczi L; Bodrogi I; Ormiston W; Daly P; Guilford P; Fossa SD; Heimdal K; Tjulandin S; Liubchenko L; Stoll H; Weber W; Forman D; Oliver T; Einhorn L; McMaster M; Kramer J; Greene M; Weber B; Nathanson K; Cortessis V; Easton D; Bishop D; Stratton M; Rapley EA, 2006, 'Genome-wide linkage screen for testicular germ cell tumour susceptibility loci', Human Molecular Genetics, 15, pp. 443 - 451

Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2006, 'Oxaliplatin and axonal Na+ channel function in vivo', Clinical Cancer Research, 12, pp. 4481 - 4484

Martin AC; Friedlander ML; Kiernan MC, 2006, 'Paraneoplastic mononeuritis multiplex in non-small-cell lung carcinoma', Journal of Clinical Neuroscience, 13, pp. 595 - 598

Phillips K; Jenkins M; Lindeman G; McLachlan S; McKinley J; Weideman P; Hopper J; Friedlander M, 2006, 'Risk management practices of Australasian BRCA1 and BRCA2 mutation carriers', European Journal of Cancer Supplements, 4, pp. 71 - 71, http://dx.doi.org/10.1016/s1359-6349(06)80114-x

Phillips KA; Milne RL; Buys S; Friedlander ML; Ward JH; McCredie MRE; Giles GG; Hopper JL, 2005, 'Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry', Journal of Clinical Oncology, 23, pp. 4679 - 4686, http://dx.doi.org/10.1200/JCO.2005.03.002

Kaern J; Aghmesheh M; Nesland JM; Danielsen HE; Sandstad B; Friedlander M; Tropé C, 2005, 'Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?', International Journal of Gynecological Cancer, 15, pp. 1014 - 1022, http://dx.doi.org/10.1111/j.1525-1438.2005.00185.x

Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips KA, 2005, 'Obesity and outcomes in premenopausal and postmenopausal breast cancer', Cancer Epidemiology Biomarkers and Prevention, 14, pp. 1686 - 1691, http://dx.doi.org/10.1158/1055-9965.EPI-05-0042

Mitchell P; Goldstein D; Michael M; Beale P; Friedlander M; Zalcberg J; Clarke S; White S, 2005, 'Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC)', Journal of Clinical Oncology, 23, pp. 3581 - 3581, http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3581

Goldstein D; Mitchell P; Friedlander ML; Michael M; Beale P; Zalcberg JR; White S; Clarke SJ, 2005, 'Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients', British Journal of Cancer, 92, pp. 832 - 837, http://dx.doi.org/10.1038/sj.bjc.6602426

Aghmesheh M; Edwards LS; Clarke CL; Byth K; Katzenellenbogen B; Russell PJ; Friedlander ML; Tucker K; de Fazio A, 2005, 'Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas', Gynecologic Oncology, 97, pp. 16 - 25, http://www.sciencedirect.com/science/article/B6WG6-4FDMYCP-5/2/f127ac58f5e70d17372bc0c7d403bfc7

Thewes B; Meiser B; Taylor AJ; Phillips KA; Pendlebury S; Capp A; Dalley D; Goldstein D; Baber R; Friedlander ML, 2005, 'Fertility - and Menoapuse-Related Information Needs of Younger Women With a Diagnosis of Early Breast Cancer', Journal of Clinical Oncology, 23, pp. 5155 - 5165

Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Friedlander ML; Andrews L; Franklin J, 2005, 'Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer', Psycho - Oncology, 14, pp. 249 - 261

Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC, 2005, 'Oxaliplatin-induced neurotoxicity and the development of neuropathy', Muscle and Nerve, 32, pp. 51 - 60

Phillips KA; Butow P; Chang J; Weideman P; Price M; McLachlan S; Lindeman G; Mckay M; Friedlander ML; Hopper JL; Stewart A, 2005, 'Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort', Familial Cancer, 4, pp. 105 - 113

Nathanson K; Kanetsky P; Hawes R; Vaughn D; Letrero R; Tucker K; Friedlander ML; Phillips KA; Hogg DW; Jewett M; Lohynska R; Daugaard G; Richard S; Chompret A; Bonati-Pellie C; Heidenreich A; Olah E; Geczi L; Bodrogi I; Ormiston W; Daly P; Oosterhuis J; Gillis A; Looijenga L; Guilford P; Fossa SD; Heimdal K; Tjulandin S; Liubchenko L; Stoll H; Weber W; Huddart R; Crockford G; Forman D; Oliver D; Einhorn L; Weber B; McMaster M; Greene M; Pike M; Cortessis V; Schwartz S; Bishop D; Easton D; Stratton M; Kramer J; Chen CW; Rapley EA, 2005, 'The Y deletion gr/gr and susceptibility to testicular germ cell tumor', American Journal of Human Genetics, 77, pp. 1034 - 1043

Thewes B; Meiser B; Duric V; Stockler M; Taylor AJ; Stuart-Harris R; Links MR; Wilcken NW; McLachlan S; Phillips KA; Beith J; Boyle FM; Friedlander ML, 2005, 'What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?', Lancet Oncology, 6, pp. 581 - 588

Aghmesheh M; Friedlander M; Russell PJ; Edwards L; Yang J-L; Kconfab K; Nesland JM; Danielson H; Kaern J; Tucker KM, 2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas', Journal of Clinical Oncology, 22, pp. 5040 - 5040, http://dx.doi.org/10.1200/jco.2004.22.90140.5040

Aghmesheh M; Friedlander M; Russell PJ; Edwards L; Yang J-L; Kconfab K; Nesland JM; Danielson H; Kaern J; Tucker KM, 2004, 'BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas', Journal of Clinical Oncology, 22, pp. 5040 - 5040, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.5040

Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips K-A, 2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer', Journal of Clinical Oncology, 22, pp. 9540 - 9540, http://dx.doi.org/10.1200/jco.2004.22.90140.9540

Loi S; Milne RL; Friedlander ML; McCredie MRE; Giles GG; Hopper JL; Phillips K-A, 2004, 'The impact of obesity on outcomes in a population-based cohort of women with early-onset breast cancer', Journal of Clinical Oncology, 22, pp. 9540 - 9540, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.9540

Rischin D; Phillips KA; Friedlander ML; Harnett P; Quinn MA; Richardson G; Martin A, 2004, 'A Phase II trial of capecitabine in heavily pre-treated platinum-resistant ovarian cancer', Gynecologic Oncology, 93, pp. 417 - 421

Hogg R; Friedlander ML, 2004, 'Biology of Epithelial Ovarian cancer: Implications for Screening Women at High Genetic Risk', Journal of Clinical Oncology, 22, pp. 1315 - 1327

Daly EB; Chen GW; Sun L; Friedlander ML; Goldstein D; Beer D; Chesterman CN; Hogg PJ, 2004, 'Blood level of phosphoglycerate kinase does not correlate with presenceor extent of tumor', International Journal of Biological Markers, 19, pp. 170 - 172

Aghmesheh M; Nesland J; Kaern J; Dorum A; Edwards LS; Byth K; Friedlander ML; Jackson P; Tucker K; Russell PJ, 2004, 'No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers', Gynecologic Oncology, 95, pp. 430 - 436, http://www.sciencedirect.com/science/article/B6WG6-4DXB995-1/2/ed6c7284e0c7d1c30ad49018f2a9cb0d

Webster GJ; Kurtovic J; Singh-Grewal I; Friedlander ML; Riordan SM, 2004, 'Prevention of hepatotoxicity but loss of antimelanoma effect withcombined fotemustine and anti-oxidant treatment', Internal Medicine Journal, 34, pp. 298 - U2

Phillips KA; Milne RL; Friedlander ML; Jenkins MA; Mccredie M; Giles GG; Hopper JL, 2004, 'Prognosis of Premenopausal Breast Cancer and Childbirth Prior to Diagnosis', Journal of Clinical Oncology, 22, pp. 699 - 705

Rapley EA; Hockley S; Warren W; Johnson L; Huddart R; Crockford G; Forman D; Leahy M; Oliver D; Tucker K; Friedlander ML; Phillips KA; Hogg D; Jewett M; Lohynska R; Daugaard G; Richard S; Heidenreich A; Geczi L; Bodrogi I; Olah E; Ormiston W; Daly P; Looijenga L; Guilford P; Aass N; Fossa SD; Heimdal K; Tjulandin S; Liubchenko L; Stoll H; Weber W; Einhorn L; Weber B; McMaster M; Greene M; Bishop D; Easton D; Stratton M, 2004, 'Somatic mutations of KIT in familial testicular germ cell tumours', British Journal of Cancer, 90, pp. 2397 - 2401

Meiser B; Tucker M; Andrews L; Tucker K; Friedlander ML; Muir A, 2004, 'The feasibility of women at high risk for breast cancer participating in chemoprevention trials: An attitudinal study', Journal of Psychosocial Oncology, 22, pp. 31 - 45

Hacker NF; Friedlander ML, 2004, 'Treatment of recurrent ovarian cancer', Chang Gung Medical Journal, 27, pp. 570 - 577, http://www.sciencedirect.com/science/article/B6WVB-4DVW7KP-2Y0/2/9a983bdc3c2e8ebecc9287dafa401635

Friedlander M; Hogg R; Phillips KA, 2003, 'Management of women at increased genetic risk of ovarian cancer', Cancer Forum, 27, pp. 151 - 156

Scott CI; Iorgulescu DG; Thorne HJ; Henderson MA; Phillips KA; Sambrook J; Chenevix-Trench G; Friedlander M; Baxter N; Evans G; Waring P; Clouston D, 2003, 'Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy', Clinical Genetics, 64, pp. 111 - 121, http://dx.doi.org/10.1034/j.1399-0004.2003.00097.x

Hogg R; Friedlander M, 2003, 'Role of systemic chemotherapy in metastatic cervical cancer', Expert Review of Anticancer Therapy, 3, pp. 234 - 240, http://dx.doi.org/10.1586/14737140.3.2.234

Tiller K; Meiser B; Reeson E; Tucker M; Andrews L; Gaff C; Kirk J; Phillips KA; Friedlander ML, 2003, 'A decision aid for women at increased risk for ovarian cancer', International Journal of Gynecological Cancer, 13, pp. 15 - 22

Tiller K; Meiser B; Reeson E; Tucker M; Andrews L; Gaff C; Kirk J; Phillips KA; Friedlander M, 2003, 'A decision aid for women at increased risk for ovarian cancer', International Journal of Gynecologic Cancer, 13, pp. 15 - 22, http://dx.doi.org/10.1136/ijgc-00009577-200301000-00003

Friedlander ML; Jones R; Ryan M, 2003, 'Carboplatin hypersentivity reactions: re-treatment with cisplatin desensitisation', Gynecologic Oncology, 89, pp. 112 - 115

Friedlander ML; Thewes B, 2003, 'Counting the costs of treatment: the reporductive and gynaecological consequences of adjuvant therapy in young women with breast cancer', Internal Medicine Journal, 33, pp. 372 - 379

Apicella C; Andrews L; Hodgson SV; Fisher SA; Lewis CM; Solomon E; Tucker K; Friedlander ML; Bankier A; Southey MC; Venter DJ; Hopper JL, 2003, 'Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defines personal and family history in an Ashkenazi Jewish woman LAMBDA', Breast Cancer Research, 5, pp. 206 - 216

Thewes B; Meiser B; Rickard J; Friedlander ML, 2003, 'The fertility and menopause-related information needs of younger women with a diagnosis of breast cancer', Psycho - Oncology, 12, pp. 500 - 511

Hogg R; Friedlander M, 2002, 'Management of embryonal carcinoma of the ovary', CME Journal of Gynecologic Oncology, 7, pp. 234 - 237

Friedlander ML, 2002, 'Guidelines for the treatment of recurrent and metastatic cervical cancer', Oncologist, 7, pp. 342 - 347

Meiser B; Butow P; Friedlander ML; Barratt AJ; Schnieden V, 2002, 'Psychological impact of genetic testing in women from high risk breast cancer families', European Journal of Cancer, 38, pp. 2025 - 2031

Tiller K; Meiser B; Butow P; Clifton M; Thewes B, 2002, 'Psychological Impact of Prophylactic Oophorectomy in Women at Increased Risk of Developing Ovarian Cancer: A Prospective Study', Gynecologic Oncology, 86, pp. 212 - 219

Leary JA; Friedlander ML, 2002, 'The molecular genetics of epithelial ovarian cancer', Current Medical Literature Gynaecology and Obstetrics, 8, pp. 1 - 7

Marx GM; Friedlander ML, 2001, 'Drug toxicity prevention and management', CME Journal of Gynecologic Oncology, 6, pp. 29 - 33

Yang JL; Friedlander ML, 2001, 'Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect', Lancet, 357, pp. 1767 - 1768, http://dx.doi.org/10.1016/S0140-6736(00)04892-3

Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D; Abdi E; Kotasek D; Beadle G; Friedlander M; Anton A; Aranda E; Murillo E; Nogueira M; Balli M; De Lena M; Lopez M; Luporini G; Micheletti E; Morrica B; Tordiglione M; Breitbach GP; Dornhoff W; Klinkenstein C; Villena C; Wilken H; Cervek J; Chacòn R; Estévez R; Mickiewicz E; Muro H; Damianov D; Donat D; Vuletic L; Gershanovich MNN; Ghilezan N; Hegg R; Jassem J; Pawlicki M; Ramlau C; Siedlecki P; Kocak I; Korec S; Muse IM; Nagykàlnai T; Perenyi L; Pinter T; Vallejos CS; Vogel C, 2001, 'Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study', Journal of Clinical Oncology, 19, pp. 943 - 953, http://dx.doi.org/10.1200/JCO.2001.19.4.943

Marx GM; Friedlander ML; Hacker NF, 2001, 'Cytotoxic drug treatment of vulval and vaginal cancer', CME Journal of Gynecologic Oncology, 6, pp. 67 - 72

Back to profile page